Tests sold by Veracyte, CareDx, Biodesix, Genomic Health, BioTheranostics, and fetal aneuploidy trisomy risk testing will see improved rates from earlier proposals.
The firm saw a 6 percent boost year over year in test volumes for its AlloMap non-invasive blood test for heart transplant patients.
Horizon will supply cell-free DNA-based molecular reference standards for inclusion in CareDx’s cfDNA testing workflows for the monitoring of transplanted organ rejection.
CMS final pricing for a number of CPT codes brings positive news for various gene sequencing procedures and multi-analyte algorithm assays.
The company had previously said it intended to use the proceeds to continue its development of its solid organ transplant diagnostic AlloSure.
The company has priced the shares at $4, and said it plans to use the proceeds to fund the continuing development of its AlloSure transplant diagnostic.
As LDT developers await an FDA decision on potential new regulations and grapple with reimbursement issues, investors may be unwilling to deal with the uncertainty.
The company said it achieved record volumes for its AlloMap non-invasive blood test for heart transplant patients.
While reimbursement and regulatory issues may make some cautious, investors are encouraged by the promise of breakthrough outcomes in a variety of applications.
Some of the proposed payment rates for 2017 are low, but diagnostics firms will likely try to negotiate higher pricing during the 30-day comment period.
In Science this week: metagenomic-based technique for determining protein structure, and more.
An academic laments the rise of narcissism in the sciences, the Guardian reports.
Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.
The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.